Alnylam Pharmaceuticals, Inc ALNY
NASDAQ · United States · Health Technology
$235.58-11.16 (-4.52%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-07-30 | 1.21 | 1.63 | -25.8% | $1.29B | -2.4% | -28.3%$286.62→$205.52 |
| Q1 2026 | 2026-04-30 | 1.99 | 1.47 | +35.4% | — | — | -1.7%$301.19→$296.11 |
| Q4 2025 | 2026-02-12 | 1.25 | 1.50 | -16.7% | — | — | -2.4%$322.28→$314.40 |
| Q3 2025 | 2025-10-30 | 2.90 | 1.75 | +65.7% | — | — | -5.3%$481.59→$456.04 |
| Q2 2025 | 2025-07-31 | 0.32 | 0.15 | +113.3% | — | — | — |
| Q1 2025 | 2025-05-01 | -0.01 | -0.37 | +97.3% | — | — | — |
| Q4 2024 | 2025-02-13 | 0.06 | -0.14 | +142.9% | — | — | — |
| Q3 2024 | 2024-10-31 | -0.50 | -0.39 | -28.2% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.